BG Medicine's Heart Test Powers 175 Percent Revenue Growth in Q4
March 13, 2013
BG Medicine's Heart Test Powers 175 Percent Revenue Growth in Q4
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- BG Medicine Fails to Meet Listing Requirement, Nasdaq Warns Firm
May 20, 2013 / GenomeWeb Daily News - BG Medicine Posts 85 Percent Jump in Q1 Revenues, Appoints New CEO
May 10, 2013 / ProteoMonitor - With Two Validation Studies Complete, Pronota Prepping Heart Failure Dx for 2014 Launch
April 26, 2013 / ProteoMonitor - Abbott Receives EU CE Mark for Automated Version of BG Medicine's Galectin-3 Test
April 12, 2013 / ProteoMonitor - Studies Shore up BG Medicine's Push for Galectin-3 Test in Hospital Readmission Risk Assessment
March 8, 2013 / ProteoMonitor